London, UK – November 10, 2026 – A stark reality is emerging from the UK’s life sciences sector: patient recruitment in industry-sponsored clinical trials has plummeted for the fifth consecutive year, a concerning trend highlighted in the Association of the British Pharmaceutical Industry’s (ABPI) latest annual report. While the speed of trial initiation has seen some improvements, the persistent decline in patient numbers and a dip in new trial starts in key phases are raising alarm bells, prompting calls for "urgent action" from industry leaders.
The report, released on November 5th, paints a troubling picture of the UK’s standing on the global stage. In the 2025/26 fiscal year, the UK has slipped further down the rankings for trial initiations. It now sits in seventh place for Phase I trials, a decline from sixth place in the previous year. Similarly, Phase II trials have seen the UK drop to fifth position. While Phase III trials have remained stable at seventh place, the overall trajectory indicates a weakening competitive position.
This downward trend is occurring as China continues its ascent, solidifying its position as the undisputed global leader in clinical trial initiations across all phases. This shift is largely attributed to the growing number of single-country studies spearheaded by Chinese pharmaceutical companies, but the rise in multi-country trials originating from China also signals a potential harbinger of future trends across subsequent trial phases.
The Shrinking Pool: Declining Patient Participation
The core of the problem lies in the diminishing number of patients engaging in clinical trials. In 2025/26, a mere 17,618 individuals participated in industry-sponsored clinical trials within the National Health Service (NHS). This represents a significant drop from the 19,507 participants recorded in the preceding year and a staggering 31% decrease compared to 2022/23 figures.
Compounding these concerns, the proportion of interventional clinical trial participants enrolled in industry-sponsored studies has fallen to just 3.8%. This is a substantial decline from the pre-pandemic era, when this figure consistently hovered above 10%, underscoring a growing disconnect between the industry’s needs and patient participation.
Chronology of Decline: A Five-Year Trend
The ABPI’s report meticulously details a five-year pattern of declining patient enrollment in UK clinical trials. This consistent downward trajectory has cast a shadow over the nation’s once-robust clinical research infrastructure.
- 2021/22: While specific figures for this year are not detailed in the provided text, the report indicates a continued trend of falling recruitment in subsequent years.
- 2022/23: A significant benchmark, showing a 31% decrease in participant numbers compared to the 2025/26 figures.
- 2024/25: The UK ranked sixth for Phase I trial initiations.
- 2025/26: Patient enrollment dropped to 17,618, and the UK slipped to seventh place for Phase I and Phase II trial initiations, remaining seventh for Phase III.
Global Shift: China’s Unprecedented Growth
The ABPI report unequivocally identifies China as the new powerhouse in the global clinical trial arena. This ascendancy is not limited to a single phase but spans across all stages of clinical development. The surge is primarily driven by an increasing number of domestic, single-country studies orchestrated by Chinese pharmaceutical firms. However, the growing prominence of multi-country trials originating from China is particularly noteworthy, suggesting a sustained and expanding influence on the global research landscape. This trend could serve as a leading indicator for future developments in subsequent trial phases, potentially reshaping the geographical distribution of clinical research investment.
Historically, Phase I trials have been a strong suit for the UK, a testament to its established research capabilities and infrastructure. However, this traditional strength appears to be eroding under the weight of a global migration of research activities towards China. The implications of this shift are profound, potentially impacting the UK’s ability to attract and retain cutting-edge research and development.
Supporting Data: A Closer Look at the Figures
The ABPI’s report provides granular data that sheds light on the complexities of the UK’s clinical trial ecosystem:
- Trial Initiations (2025/26):
- Phase I: UK ranked 7th (down from 6th in 2024/25)
- Phase II: UK ranked 5th (down one place)
- Phase III: UK ranked 7th (unchanged)
- Patient Recruitment (2025/26):
- Total participants in industry clinical trials in the NHS: 17,618
- Decrease from the previous year: 19,507 participants
- Decrease compared to 2022/23: 31%
- Proportion of Industry-Sponsored Interventional Trials: 3.8% (down from >10% pre-pandemic)
- Speed of Trial Setup:
- Percentage of studies opened to patients within 60 days of approval (2025/26): 35% (against a target of 90%)
- Percentage of studies recruiting their first patient within 30 days of opening: 53%
Bright Spots Amidst the Gloom: Commercial Research Delivery Centres (CRDCs)
Despite the overarching challenges, the report does highlight a positive development: the UK’s Commercial Research Delivery Centres (CRDCs). Funded as part of the VPAG Investment Programme, these centres are demonstrating superior performance in trial set-up and delivery compared to the broader UK ecosystem. In 2025/26, a significant 75% of CRDC studies were open to recruitment within 60 days of approval, a marked improvement over the 58% observed across all UK sites. This suggests that targeted investment and strategic focus can yield tangible results, offering a potential model for broader application.
Furthermore, initiatives like the improved National Contract Value Review process are showing early promise. This reform has dramatically reduced the time required to finalize contracts and costing for participating trial sites, bringing it down from 65 days to just 25 days. Such efficiencies are crucial for streamlining the clinical trial process and making the UK a more attractive destination for research.
Official Responses and Government Ambitions
The government has set ambitious targets to bolster clinical trial participation. The stated aim is to double the number of individuals involved in industry trials by 2026, and then double it again by 2029. The ABPI supports this ambition, and there have been some encouraging signals, such as an August 2026 achievement where every study received an approval decision within 60 days.
However, the report underscores that these initial speed improvements do not fully translate into faster recruitment. The time taken for studies to open to patient enrollment, to recruit the first patient, and to activate all necessary sites remain significant bottlenecks.
Joe Edwards, Executive Director of UK Competitiveness at the ABPI, expressed his concerns: "Industry clinical trials offer patients invaluable opportunities to access cutting-edge treatments, often when no other options are available. The continued decline in UK recruitment is deeply worrying. While the government, regulators, and the NHS have made commendable progress in speeding up trial initiation, the full benefits are only realized by patients, the NHS, and the economy when this speed is matched by effective recruitment. Companies invest in clinical trials where all sites can open swiftly and recruit reliably. The UK must now achieve this across the entire trial process, not just at the initial stage."
Implications and Recommendations for Growth
The ABPI’s report concludes with a series of five critical recommendations aimed at revitalizing the UK’s clinical trial sector. These proposals are directed towards governments across the UK, the NHS, and the industry itself:
- Expand UK Clinical Research Delivery Metrics and Funding: The ABPI advocates for the expansion of metrics and research delivery funding to comprehensively support study implementation across all sites. This would also serve to incentivize more ambitious and predictable recruitment strategies.
- Establish a UK-Wide Patient Recruitment Service: A call is made for the creation of a nationwide service that leverages NHS data to identify and enroll suitable patients for trials. This would streamline the recruitment process and ensure a more efficient flow of participants.
- Measure and Report on Participant Diversity: To foster more inclusive and representative research, the ABPI recommends the systematic measurement and reporting of diversity among clinical trial participants. This will ensure that trial outcomes reflect the broader population.
- Strengthen the UK’s Viability as a Trial Location: The report emphasizes the need to enhance the UK’s attractiveness as a trial destination by ensuring its medicines access and adoption environment provides globally competitive patient care. This aligns with the commitment to double innovative medicines spend by 2036.
- Reinvest Income in Research Infrastructure: To secure the long-term sustainability of the UK’s trial system, the ABPI suggests reinvesting income generated from industry trials back into research staff and facilities.
Recent Reforms and Lingering Skepticism
In April 2026, the UK implemented significant reforms to its clinical trial framework, the first major overhaul in two decades. These changes, which gained parliamentary approval, include expedited assessment for first-in-human trials and the introduction of "notifiable trials" – a fast-track route for lower-risk studies to commence sooner and undergo quicker modifications, all while maintaining stringent safety standards. The reforms also embrace novel approaches, such as utilizing early safety data from overseas studies that meet UK standards and employing computer model simulations to predict drug behavior before human testing.
While these reforms are intended to make the UK a more appealing hub for clinical research, experts remain divided on whether the regulatory changes alone are sufficient to reverse the current downward trend. The underlying issues of patient recruitment and global competition require a more comprehensive and sustained approach. The coming years will be critical in determining whether the UK can regain its footing in the dynamic and increasingly competitive landscape of global clinical trials.
About the Author
